AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06519773 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Modified periosteal inhibition
Description: After local anathesia, a traumatic extraction of the hopeless tooth will be made trying as much as possible to preserve the labial plate of bone and overlying soft tissue.~* Once the tooth is extracted, the socket is gently debrided and irrigated using sterile saline solution. Then the dental implant provided by Auto Fit Dental Implant is placed in the best prosthetic driven position, following the guidelines for immediate implants using prefabricated computer guided surgical template.~* After accurate implant placement, a full-thickness flap will be elevated at mesial and distal papilla making a buccal envelope. A bone lamina and provided by GRANNTIE 1 mm thickness will be trimmed and hydrated in sterile saline solution for 30 s to soften it; it should be 1-2 mm larger and deeper than the vestibular bone.
Study NCT04564976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social support image
Description: An image of a social support figure specific to each participant (provided by the participant) will be present while participants undergo a fear acquisition procedure. Specifically--the image will be presented alongside a neutral image that is either consistently paired with shock (CS+) or never paired with shock (CS-), so that assessment of whether there are differences in fear responding (evaluated via SCR) due the shock pairing can be assessed. This is a typical fear acquisition procedure, and a typical outcome would be for SCR to be higher for the CS+ compared to the CS- toward the end and following the procedure, indicating that the CS+ is now associated with the aversive shock and is bringing about a fear response (in this case indexed by increased sympathetic nervous system activity preparing the body to fight or flee).
Study NCT04994379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 mA tDCS
Description: One session with stimulation intensity of 1 mA.
Study NCT04994379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1.5 mA tDCS
Description: One session with stimulation intensity of 1.5 mA.
Study NCT04994379 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: One session of sham stimulation.
Study NCT05024630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal artery cryoablation
Description: Renal denervation were achieved by cryoablation of renal artery with cryoballoon.
Study NCT05024630 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Pulmonary vein cryoablation
Description: Pulmonary vein isolation was achieved by cryoablation of pulmonary veins with cryoballoon.
Study NCT05024630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein cryoablation
Description: Pulmonary vein isolation was achieved by cryoablation of pulmonary veins with cryoballoon.
Study NCT05024630 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Renal arteriography
Description: Renal artery was examined by renal arteriography
Study NCT04877795 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Blood will be sampled from enrolled patients and analyzed for levels of troponin, copeptin and heart-type fatty acid binding protein (HFABP).
Study NCT04871165 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: S-binding IgG, RBD-binding IgG and N-binding IgG immunoassays and SARS-CoV-2 serum neutralization assay, quantitative serum immunoglobulin tests
Description: S-binding IgG, RBD-binding IgG and N-binding IgG immunoassays and SARS-CoV-2 serum neutralization assay, quantitative serum immunoglobulin tests.
Study NCT04871165 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of proinflammatory cytokine production and immunophenotypic analysis after stimulation with overlapping S-peptides in peripheral blood mononuclear cells (PBMC)
Description: Quantitative evaluation of proinflammatory cytokine (IFN-gamma, IL-2 and IL-4) production after stimulation with overlapping S-peptides in peripheral blood mononuclear cells and immunophenotypic analysis (CD45, CD3, CD4, CD8, CD16, CD56, CD14, CD19)
Study NCT04871165 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative sequencing for TCR repertoires for SARS-CoV-2-specific antigens
Description: Quantitative sequencing for TCR repertoires for SARS-CoV-2-specific antigens
Study NCT06388681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Effect of Stress Ball Use on Immobilization Comfort, Pain Level and Vital Signs in Patients Undergoing Coronary Angiography
Description: The researchers will explain and demonstrate to the intervention group how to use the stress ball. Then, the patient will be asked to use the ball and it will be confirmed whether he/she uses it correctly. After angiography, it will be stated that the patients in the intervention group should count to 5 and squeeze it once for 10 minutes every hour and rotate with the right hand and left hand until they are mobilized.
Study NCT06412484 — intervention group
Intervention type: BEHAVIORAL
Intervention: Pain Free Session
Description: On a day in which participants don't have any pain or a pain ranging from 0-2 (on a numerical rating scale of 0-10), they will undergo all the study measures (see primary outcome measures for detail): clinical exam, QST, SSRs, CPM, rsMRI, lumbar MRI, MRS, and blood sample.
Study NCT06412484 — intervention group
Intervention type: BEHAVIORAL
Intervention: Low Back Pain Session (= clinically relevant pain)
Description: On a day in which patients have an ongoing typical low back pain episode of an intensity of 3 or more (on a numerical rating scale of 0-10), they will undergo all the study measures (see primary outcome measures for detail), except the lumbar MRI: clinical exam, QST, SSRs, CPM, rsMRI, MRS, and blood sample.
Study NCT06412484 — intervention group
Intervention type: BEHAVIORAL
Intervention: Experimental Pain Session (= clinically irrelevant pain)
Description: On a day in which participants don't have any pain or a pain ranging from 0-2 (on a numerical rating scale of 0-10), an experimental pain state will be induced using a high concentration (8%) Qutenza patch, containing capsaicin. All the study measures will be performed (see primary outcome measures for detail), except the lumbar MRI and blood sample: clinical exam, QST, SSRs, CPM, rsMRI, MRS.
Study NCT05290051 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Optical Genome Mapping (Bionano®)
Description: Search for chromosome abnormalities through alteration of the optical map of the genome compared to reference genome using the Bionano® 's pipeline.
Study NCT05290051 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Longread sequencing (Nanopore®)
Description: Search for chromosome abnormalities from the sequencing data obtain from high molecular weight DNA molecules using dedicated analysis pipeline.
Study NCT05118724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 840mg i.v., on Day 1 and Day 15 (q2w) of every 28-day treatment cycle for a total of 12 cycles (24 doses)
Study NCT05059834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online mindfulness resources
Description: a free mindfulness resource online for patients with general anxiety disorder
Study NCT05059834 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: usual care
Description: patient will continue to receive drug and advice from doctors and nurses for their anxiety disorder
Study NCT06146023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic anastomosis (Symani surgical system and RoboticScope)
Description: Robot-assisted microvascular anastomosis on 1.0-mm-diameter silicone vessels using the Symani surgical system and RoboticScope
Study NCT06146023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional anastomosis
Description: Conventional microvascular anastomosis on 1.0-mm-diameter silicone vessels using conventional microsurgical instruments and conventional surgical microscope
Study NCT04626583 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic MSC
Description: Subconjunctival Injection of Allogeneic Mesenchymal Stromal Cells
Study NCT05805709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Physician/Advance Practice Provider
Description: The nephrologist and/or nephrology-associated advanced practice provider (APP) at each site will lead the intervention team for the duration of the study. The study physicians will fulfil two main roles: (a) Provide supervision to the rest of the study team and (b) conduct a discharge assessment to triage and make recommendations for follow-up care.
Study NCT05805709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse Navigator
Description: The nurse navigator will be the primary contact for the participants assigned to the intervention group for the study. The navigator will obtain contact information, information about the patient's usual care providers and pharmacy, review medications, show the participant how to use the home blood pressure machine and scales and arrange for follow-up visits. The role of the nurse navigator will be to monitor the participant's medical condition; facilitate scheduling of needed medical follow-up including both routine (pre-scheduled) and ad hoc (urgent or emergency); enhance adherence with prescribed medical care and follow-up appointments; and serve as a resource to the patient to answer questions about their AKI-related management, facilitate medical and associated care and provide enhanced psychosocial support.
Study NCT05805709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist
Description: The pharmacist will complete the medication reconciliation and medication regimen review per the predetermined checklist, via telemedicine if agreeable to the patient. The goal of the patient/caregiver-pharmacist interaction is to cover the following: avoidance of nephrotoxins when possible and appropriate, appropriate dosing of renally cleared drugs, review for drug-drug interactions, monitoring appropriate use of chronic medications, medication adherence, monitor for adverse drug reactions, evaluation of non-prescription medication use, medication/disease education and social support.
Study NCT05805709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Written information about kidney disease, nephrotoxins to be avoided and importance/need for follow up with a physician will be provided.
Study NCT05805709 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education
Description: Written information about kidney disease, nephrotoxins to be avoided and importance/need for follow up with a physician will be provided.
Study NCT05512247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meal Delivery
Description: 10 home-delivered meals per week provided by a local meal delivery company + brief weekly behavioral support with study staff
Study NCT05538273 — intervention group
Intervention type: OTHER
Intervention: Early removal of urinary catheter postoperatively
Description: removal of urinary catheter less than 24 hours after surgery
Study NCT05538273 — intervention group
Intervention type: OTHER
Intervention: Late removal of urinary catheter postoperatively
Description: removal of urinary catheter greater than 24 hours after surgery
Study NCT05226026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NiteCAPP HELPS
Description: 4 weeks of NiteCAPP (a digital version of CBT-I recently developed at Mizzou)
Study NCT05226026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tapered Withdrawal
Description: Gradual tapered withdrawal following CDC guidelines, with additional check-ins and motivational interviewing with a therapist.
Study NCT05226026 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tapered Withdrawal
Description: Gradual tapered withdrawal following CDC guidelines, with additional check-ins and motivational interviewing with a therapist.
Study NCT04992962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD/CBN
Description: A water-soluble sublingual tablet containing 10 mg of CBD and 10 mg of CBN.
Study NCT04992962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD/THC
Description: A water-soluble sublingual tablet containing 10 mg of CBD and 5 mg of THC.
Study NCT04992962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An inactive compound.
Study NCT05848622 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Real-time gait biofeedback
Description: The RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 5th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
Study NCT05848622 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham real-time gait biofeedback
Description: The Sham RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 5th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
Study NCT04921007 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacral ESP block
Description: A high-frequency ultrasound linear probe covered with a sterile sheath will be placed longitudinally to the midline of the sacrum. The median sacral crests and erector spinae muscle will be visualized, then a 22-gauge, 50 mm needle will be advanced from cranial to caudal direction until its tip touch the sacral crest.
Study NCT04921007 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block
Description: A high-frequency ultrasound linear probe covered with a sterile sheath will be placed on to the sacrococcygeal region. The dura mater, epidural space, conus medullaris, sacral cornua, and sacrococcygeal ligament will be identified. Using the in-plane technique, a 22-gauge, 50 mm needle will be introduced to reach the sacral epidural space.
Study NCT04921007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Following negative aspiration, a precalculated dose (0.5 ml/kg) of 0.25% bupivacaine will be injected.
Study NCT04586998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exhaled drug monitor Edmon
Description: Taking samples of exhaled breath every minute during elective surgery in comparison to blood samples taken at predefined time points.
Study NCT06227208 — intervention group
Intervention type: DEVICE
Intervention: Continuous vital sign monitoring
Description: Wireless monitoring system that provided continuous, non-invasive collection of their vital signs, including peripheral oxygen saturation (SpO2) and respiratory rate (RR), for up to 92 hours following surgery or until discharge. The respiratory rate was monitored via FDA-approved Isansys Lifetouch electrocardiogram (ECG) patch, which was placed on the left side of the chest. SpO2 levels were continuously recorded using the Nonin WristOx 3150, a wrist-mounted finger oximeter.
Study NCT04464265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Propofol will be administered by intravenous infusion. All anesthesia equipment, supplies, and drugs will be provided by anesthesiologists from the University of Michigan Health System. The researchers will manually control the infusion of propofol to achieve target effect-site concentrations which will be maintained for 4 minutes each.~Four types of music, including Jazz, Rock, Pop and Country, will be presented in a pseudo-randomized order. During the behavioral test period, participants will be asked to squeeze an Magnetic Resonance Imaging (MRI) compatible grip dynamometer (a rubber ball) for every 10-second periods (96 cycles in total). The beginning of each cycle will be cued with the spoken word squeeze.
Study NCT05474066 — intervention group
Intervention type: DEVICE
Intervention: ERP Testing
Description: * Attention \& Concentration:~* Continuous Visual Memory Test (CVMT):~* Flanker Task:~* Hayling Test:
Study NCT05742503 — intervention group
Intervention type: OTHER
Intervention: Depo-Provera
Description: Injectable progesterone
Study NCT05742503 — intervention group
Intervention type: OTHER
Intervention: Implanon
Description: Etonogestrel implant
Study NCT05742503 — intervention group
Intervention type: OTHER
Intervention: Norgestrel
Description: Pill containing progesterone
Study NCT05742503 — intervention group
Intervention type: OTHER
Intervention: Mirena
Description: Levonorgestrel-releasing intra-uterine drug (IUD)
Study NCT05398887 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low radiation dose CT
Description: Underwent low dose chest CT with 30% lower radiation dose
Study NCT05398887 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Underwent ultra dose chest CT
Description: Underwent ultra dose chest CT with 90% lower radiation dose
Study NCT05398887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence based model
Description: Deep-learning based contrast boosting algorithms
Study NCT06435754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention group Vestibular Socket Preservation
Description: After atraumatic extraction Vestibular access horizontal incision will be made at the socket site, at the mucco-buccal fold. Subperiosteal tunnel will be created from the facial aspect of the socket orifice and extending apically until the extent of the vestibular access incision. A cortical shield will be introduced from the vestibular incision through the tunnel and the Socket will be filled by xenograft . Apical cut will be made at the palatal aspect to free the pedicle flap connective tissue and the pedicle flap will be raised using periosteal elevator and rotated and rolled occlusally to seal the socket and sutured using interrupted sutures . The primary palatal flap will be sutured in place over the donor site palatally using interrupted sutures.
Study NCT06435754 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group ice cream cone technique
Description: After atraumatic extraction Collagen barrier membrane will be shaped as an ice cream cone and placed in the extraction socket lining the buccal tissues. The socket will be filled with Demineralized Bovine Bone Matrix DBBM.The upper part of the membrane will be used to cover the socket and will be stabilized by interrupted sutures using prolene sutures of size 6-0
Study NCT05082116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa pegol (N8-GP)
Description: N8-GP will be injected into a vein (intravenous injections) every 4 days in at least 28 weeks
Study NCT06296745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 15 mg was administered with dexamethasone 5 mg via intraventricular or via lumbar puncture. First, induction intrathecal chemotherapy, twice per week for 2 weeks; then consolidation intrathecal chemotherapy, once per week for 4 weeks; and maintenance intrathecal chemotherapy, once per month until disease progression or unmanageable drug-related toxicity.
Study NCT05192304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN-672
Description: single dose of TPN-672 maleate tablet
Study NCT05915897 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Specimen Donation
Description: blood donation
Study NCT05793177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Everyday Life is Rehabilitation
Description: Behavior change intervention focuses on implementing more movement into everyday life using action planning, goal setting, and fatigue management.
Study NCT06102577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1gr. Vitamine C
Description: Take 1g. of vitamin C at the end of an osteopathic manual treatment
Study NCT06102577 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 1gr Placebo
Description: ake 1g. of placebo at the end of an osteopathic manual treatment
Study NCT06102577 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control group
Description: control
Study NCT04970043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab+ pemetrexed + platinum
Description: Induction period: (4-6 cycles) Camrelizumab: a fixed dose of 200 mg, intravenous drip for 30-60 minutes, the first day, every 3 weeks as a cycle.~Pemetrexed: 500 mg / m2, given on the first day, every 3 weeks as a cycle; Carboplatin: AUC = 4-5, given on the first day, every 3 weeks as a cycle; After 4-6 cycles of treatment, the patients entered the maintenance treatment period of carrizumab combined with pemetrexed.~Maintenance treatment period:~Camrelizumab: a fixed dose of 200 mg, intravenous drip for 30-60 minutes, the first day, every 3 weeks as a cycle.~Pemetrexed: 500 mg / m2, given on the first day, every 3 weeks as a cycle; Every 3 weeks is a treatment cycle, and the drug is maintained until the following conditions occur: disease progression, intolerable toxicity, or receiving immunotherapy for no more than 35 cycles (2 years).
Study NCT05432869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ES and lifestyle advices
Description: The lifestyle advices include fluid consumption, diet, weight control, constipation, smoking, etc.~External electrical stimulation will be applied for 30 minutes 3 days a week during 4 weeks. Electrodes were placed on the thighs.
Study NCT05432869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle advices
Description: The lifestyle advices include fluid consumption, diet, weight control, constipation, smoking, etc.
Study NCT06159192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity extracorporeal shock wave
Description: Extracorporeal shock wave therapy generator: Wonjin beauty SW10 shock wave therapy system made in Korean.